The association between hyperandrogenemia and the metabolic syndrome in morbidly obese women

Diabetology & Metabolic Syndrome

J. Hjelmesæth²  D. Hofsø¹  P.O. Dale³  N. Nordstrand¹  J.K. Hertel¹  T.G. Valderhaug⁴ 

[1] Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg, Norway;Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway;Department of Surgery, Vestfold Hospital Trust, Tønsberg, Norway;Division of Medicine and Laboratory Sciences, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

关键词: Metabolic syndrome;    Hyperandrogenemia;    Insulin resistance;    Morbid obesity;   

Others  :  1211822
DOI  :  10.1186/s13098-015-0040-5

 received in 2015-02-18, accepted in 2015-05-05,  发布年份 2015

【 摘 要 】

Background

Female abdominal obesity is associated with hyperandrogenemia (HA), but few studies have addressed the possible association between HA and metabolic syndrome (MetS) among obese women. Some studies indicate that insulin resistance may cause HA through different mechanisms. On the other hand, a bidirectional relationship between HA and insulin resistance has been suggested. Thus, we aimed to investigate if morbidly obese women with HA had higher odds of MetS and its components than those without HA (controls), independent of polycystic ovarian syndrome (PCOS) status.

Methods

This cross-sectional study comprised 1900 consecutive treatment seeking morbidly obese women <50 years. Free testosterone index (FTI) >0.6 defined HA. Women with previously diagnosed PCOS and those with oligo- / anovulation combined with clinical or biochemical hyperandrogenism were defined as having PCOS. Multiadjusted associations between HA and MetS were assessed by logistic regression analysis.

Results

Out of 1900 morbidly obese women, 1089 (57 %), 846 (45 %) and 312 (16 %) had MetS, HA and PCOS, respectively. Compared with controls (without HA), women with HA were younger (34 [1] years vs. 39 [2], p < 0.001) had a higher prevalence of MetS (62 % vs. 53 %, p < 0.001), type 2 diabetes (18 % vs. 15 %, p = 0.045), low HDL-cholesterol (65 % vs. 48 %, p < 0.001) and hypertriglyceridemia (48 % vs. 41 %, p = 0.004), but a lower prevalence of raised blood pressure (53 % vs. 59 %, p = 0.014). Multivariable analyses showed that HA was associated with increased odds of MetS (OR 1.61 [95 % CI 1.27, 2.02]), dysglycemia (1.65 [1.28, 2.11]), low HDL-cholesterol (1.58 [1.27, 1.97]), and hypertriglyceridemia (1.43 [1.15, 1.79]). After stratification for the presence of PCOS, the results remained largely unchanged in women without PCOS; MetS (1.52 [1.18, 1.96), dysglycemia (1.71 [1.30, 2.25]), low HDL-cholesterol (1.55 [1.22, 1.98]) and hypertriglyceridemia (1.36 [1.06, 1.74]).

Conclusion

Morbidly obese women with HA had an approximately 1.5-fold increased odds of having MetS even in the absence of PCOS. Randomized controlled clinical trials, including therapeutic strategies to lower free testosterone levels, are however necessary to explore any cause-and-effect relationship.

【 授权许可】

   
2015 Valderhaug et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ: The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010, 25:544-551.
• [2]Yildiz BO, Knochenhauer ES, Azziz R: Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008, 93:162-168.
• [3]Diamanti-Kandarakis E, Dunaif A: Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012, 33:981-1030.
• [4]Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF: Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006, 166:2081-2086.
• [5]Teede H, Deeks A, Moran L: Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010, 8:41. BioMed Central Full Text
• [6]Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al.: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009, 91:456-488.
• [7]Lim SS, Norman RJ, Davies MJ, Moran LJ: The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev 2013, 14:95-109.
• [8]Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al.: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991, 72:83-89.
• [9]Holmang A, Larsson BM, Brzezinska Z, Bjorntorp P: Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 1992, 262:E851-E855.
• [10]Nohara K, Laque A, Allard C, Munzberg H, Mauvais-Jarvis F: Central mechanisms of adiposity in adult female mice with androgen excess. Obesity (Silver Spring) 2014, 22:1477-1484.
• [11]Polotsky AJ, Allshouse A, Crawford SL, Harlow SD, Khalil N, Santoro N, et al.: Relative contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women. J Clin Endocrinol Metab 2012, 97:E868-E877.
• [12]Ehrmann DA: Polycystic ovary syndrome. N Engl J Med 2005, 352:1223-1236.
• [13]Lachelin GC, Barnett M, Hopper BR, Brink G, Yen SS: Adrenal function in normal women and women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1979, 49:892-898.
• [14]Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al.: Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010, 95:2038-2049.
• [15]Chang AY, Ayers C, Minhajuddin A, Jain T, Nurenberg P, de Lemos JA, et al.: Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. Clin Endocrinol (Oxf) 2011, 74:89-96.
• [16]Moran L, Teede H: Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009, 15:477-488.
• [17]Morris DH, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ: Body mass index, exercise, and other lifestyle factors in relation to age at natural menopause: analyses from the breakthrough generations study. Am J Epidemiol 2012, 175:998-1005.
• [18]Overlie I, Moen MH, Morkrid L, Skjaeraasen JS, Holte A: The endocrine transition around menopause–a five years prospective study with profiles of gonadotropines, estrogens, androgens and SHBG among healthy women. Acta Obstet Gynecol Scand 1999, 78:642-647.
• [19]Wallace WH, Kelsey TW: Human ovarian reserve from conception to the menopause. PLoS One 2010., 5Article ID e8772
• [20]World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects JAMA 2000, 284:3043-3045.
• [21]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [22]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
• [23]Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84:3666-3672.
• [24]Tosi F, Di SD, Kaufman JM, Bonin C, Moretta R, Bonora E, et al.: Total body fat and central fat mass independently predict insulin resistance but not hyperandrogenemia in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2014, 2:661-669.
• [25]Free testosterone indeks (FTI) in serum. Hormone Laboratory Oslo University Hospital Aker. http://www.oslouniversitetssykehus.no/omoss_/avdelinger_/hormonlaboratoriet_/analyser_/Sider/fri-testosteron-indeks-i-serumfti.aspx. Accessed 15-12-2014.
• [26]Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod. 2004, 19:41-47.
• [27]Monge M, Jean G, Bacri JL, Lemaitre V, Masy E, Joly D, et al.: Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods. Clin Chem Lab Med 2009, 47:362-366.
• [28]Polotsky AJ, Allshouse AA, Crawford SL, Harlow SD, Khalil N, Kazlauskaite R, et al.: Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. J Clin Endocrinol Metab 2014, 99:2120-2127.
• [29]Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, et al.: The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996, 81:952-960.
• [30]Diamanti-Kandarakis E: Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes (Lond) 2007, 31(Suppl 2):S8-13.
• [31]Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:1929-1935.
• [32]Legro RS, Urbanek M, Kunselman AR, Leiby BE, Dunaif A: Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertil Steril 2002, 78:51-57.
• [33]Somboonporn W, Davis S, Seif MW, and Bell, R. Testosterone for peri- and postmenopausal women. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004509.pub2/pdf
• [34]Wang X, Smith GI, Patterson BW, Reeds DN, Kampelman J, Magkos F, et al.: Testosterone increases the muscle protein synthesis rate but does not affect very-low-density lipoprotein metabolism in obese premenopausal women. Am J Physiol Endocrinol Metab 2012, 302:E740-E746.
• [35]Chen MJ, Yang WS, Yang JH, Hsiao CK, Yang YS, Ho HN: Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS. Hum Reprod 2006, 21:2266-2271.
• [36]Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16:1995-1998.
• [37]Vrbikova J, Dvorakova K, Grimmichova T, Hill M, Stanicka S, Cibula D, et al.: Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome. Clin Chem Lab Med 2007, 45:639-644.
• [38]Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS: Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension 2007, 49:1442-1447.
• [39]Muti P, Trevisan M, Panico S, Micheli A, Celentano E, Freudenheim JL, et al.: Body fat distribution, peripheral indicators of androgenic activity, and blood pressure in women. Ann Epidemiol 1996, 6:181-187.
• [40]Daka B, Rosen T, Jansson PA, Larsson CA, Rastam L, Lindblad U: Low sex hormone-binding globulin is associated with hypertension: a cross-sectional study in a Swedish population. BMC Cardiovasc Disord 2013, 13:30. BioMed Central Full Text
• [41]Roy P, Alevizaki M, Huhtaniemi I: In vitro bioassays for androgens and their diagnostic applications. Hum Reprod Update 2008, 14:73-82.